-transparent.png){kind=logo}
Six patients with advanced arteriosclerosis obliterans in the lower extremities were subjected to an exercise test on a tread mill with and without dipyridamole treatment. Prostacyclin (PGI2) release was measured by the concentration of its stable metabolite, 6-keto-prostaglandin F1 alpha in plasma. All the patients suffered from ischemic pain during both tests, but no changes were seen in plasma 6-keto-PGF1 alpha. Dipyridamole did not affect the physical performance. Our results suggest that atherosclerotic vessels do not increase PGI2 production in response to ischemia and that a single dose of dipyridamole does not change PGI2 production.
Related Publications
L Viinikka, and
P Kärkölä, and
R Pokela, and
O Ylikorkala
April 1982,
Thrombosis and haemostasis,
L Viinikka, and
P Kärkölä, and
R Pokela, and
O Ylikorkala
June 1982,
Pharmacological research communications,
L Viinikka, and
P Kärkölä, and
R Pokela, and
O Ylikorkala
January 1985,
Advances in prostaglandin, thromboxane, and leukotriene research,
L Viinikka, and
P Kärkölä, and
R Pokela, and
O Ylikorkala
September 1986,
Biochemical pharmacology,
L Viinikka, and
P Kärkölä, and
R Pokela, and
O Ylikorkala
May 1979,
Lancet (London, England),
L Viinikka, and
P Kärkölä, and
R Pokela, and
O Ylikorkala
April 1990,
Thrombosis research,
L Viinikka, and
P Kärkölä, and
R Pokela, and
O Ylikorkala
March 1998,
Angiology,
L Viinikka, and
P Kärkölä, and
R Pokela, and
O Ylikorkala
January 1981,
European journal of clinical pharmacology,
L Viinikka, and
P Kärkölä, and
R Pokela, and
O Ylikorkala
August 1984,
Lancet (London, England),
L Viinikka, and
P Kärkölä, and
R Pokela, and
O Ylikorkala
April 1988,
Journal of interferon research,
